Nektar Therapeutics reported $55M of revenue over the trailing twelve months, −27% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $55M (to Q2 2026). Net income: −$157M, trailing twelve months to Q2 2026. Free cash flow: −$234M, trailing twelve months to Q2 2026. Operating margin: −293%, trailing twelve months to Q2 2026.

NKTRNektar Therapeutics

Healthcare

$41.14-25% 1Y

$41.14

$35.1252 weeks$100.35

NKTR as reported

Nektar Therapeutics reported $55M of revenue over the trailing twelve months, −27% on the year before. 10 reported series are charted on this page, each one as filed.

$55M

Revenue, trailing twelve months · to Q2 2026 · −27% against the twelve months before

Net income: −$157M
Net income · +29% year on year · trailing twelve months to Q2 2026
Free cash flow: −$234M
Free cash flow · +26% year on year · trailing twelve months to Q2 2026
Operating margin: −293%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for NKTR, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$55M	−27%	Q2 2026
Net income	−$157M	+29%	Q2 2026
EPS	−$6.51	−25%	Q2 2026
Gross margin	100%	n/a	Q4 2025
Operating margin	−293%	n/a	Q2 2026
Net margin	−320%	n/a	Q2 2026
ROE	−92%	n/a	Q2 2026
ROA	−33%	n/a	Q2 2026
Free cash flow	−$234M	+26%	Q2 2026
P/E	11.0	n/a	Q1 2019 · 29 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.